LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Trial details
- Registry ID
- NCT06216301
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 | NovoCure GmbH | Phase 3 | Recruiting | 2028-10Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |